Malignant neoplasm of prostate
J&J’s Akeega Advances PARP Inhibition in Prostate Cancer, but FDA Pathway in Broader Patient Subsets Remains Unclear
Akeega; J&J; prostate cancer; PARP inhibitor; FDA approval; BRCA mutations; HRR gene alterations; AMPLITUDE study; metastatic castration-sensitive prostate cancer (mCSPC); metastatic castration-resistant prostate cancer (mCRPC)
J&J Presents First Survival Data for KLK2-Targeted Bispecific Pasritamig in Prostate Cancer at ASCO 2025
Johnson & Johnson; pasritamig; bispecific antibody; ASCO 2025; prostate cancer; KLK2; metastatic castration-resistant prostate cancer (mCRPC); survival data; immunotherapy
FDA Advisory Committee Unanimously Votes Against Expanding Pfizer’s Prostate Cancer Drug Combo
FDA; advisory committee; Pfizer; Talzenna; talazoparib; enzalutamide; prostate cancer; mCRPC; PARP inhibitor; label expansion; unanimous vote
MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results
MacroGenics, vobra duo, antibody-drug conjugate, B7-H3, prostate cancer, TAMARACK trial, discontinued development, safety concerns
Candel Therapeutics Sees Dramatic Stock Surge Following Successful Phase III Prostate Cancer Trial
Candel Therapeutics, CAN-2409, Phase III trial, prostate cancer, viral immunotherapy, stock surge, FDA approval
AstraZeneca’s Truqap Achieves Phase III Success in Prostate Cancer, Reviving Hopes After Breast Cancer Setback
AstraZeneca, Truqap, prostate cancer, Phase III trial, PTEN-deficient metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT).
AstraZeneca’s Truqap Achieves Phase 3 Success in Prostate Cancer, Paving Way for Label Expansion
AstraZeneca, Truqap, prostate cancer, Phase 3 trial, CAPItello-281, PTEN-deficient, metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT)
ESSA Pharma Terminates Masofaniten Development After Phase 2 Trial Failure in Prostate Cancer
ESSA Pharma, Masofaniten, Prostate Cancer, Phase 2 Trial, Enzalutamide, Xtandi, Clinical Trial Termination
Pfizer Secures EU Approval for TALZENNA in Combination with XTANDI for Metastatic Castration-Resistant Prostate Cancer
TALZENNA, XTANDI, metastatic castration-resistant prostate cancer (mCRPC), PARP inhibitor, European Commission approval, prostate cancer treatment.
Comparative Efficacy of J&J’s Erleada and Astellas/Pfizer’s Xtandi in Non-Metastatic Prostate Cancer: Real-World Study Insights
Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), Erleada (Apalutamide), Xtandi (Enzalutamide), Real-World Study, Comparative Efficacy, Safety Profiles